Editor’s note: Recently, CVS Caremark reversed its decision to exclude Eliquis (apixaban) from its formulary. This is an update to previous posts on this issue – “CVS Caremark Formulary Exclusion of Eliquis is a Patient Safety Risk,” “Non-Medication Switching is a Patient Safety Issue,” and “How a Patient Battled with CVS Caremark and Won”

By Michael Wong, JD (Founder & Executive Director, Physician-Patient Alliance for Health & Safety)

CVS Caremark Puts Patients First By Putting Eliquis Back on Formulary

CVS Caremark has put patients first by putting Eliquis® (apixaban) back on its formulary. By doing so, they have stayed true to their motto – “Your health is our priority. At CVS Caremark, each and every one of us is dedicated to helping you on your path to better health.”

Now, I can’t say the same thing about its decision at the end of 2021, but I’ll let you be the judge of that. In its original decision, CVS Caremark (part of CVS Health) decided to exclude Eliquis from the CVS Caremark Preferred Drug List. Eliquis is “indicated to reduce the risk of stroke and systemic embolism in patients with NVAF. Eliquis is indicated for the treatment of DVT [deep vein thrombosis] and PE [pulmonary embolism], and to reduce the risk of recurrent DVT and PE following initial therapy.” Eliquis is a Factor Xa inhibitor and is a Direct Oral Anticoagulant (DOAC). 

Continue reading “CVS Caremark’s Decision Putting Eliquis Back on Its Formulary Benefits Patients” →